Can a 'Clean-Up' drug make chemo safer for brain lymphoma?

NCT ID NCT03684980

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether adding glucarpidase (Voraxaze) to standard methotrexate and rituximab can safely lower methotrexate levels in the blood for people with central nervous system lymphoma. About 58 participants will receive different doses of methotrexate along with glucarpidase to see how well it reduces drug levels and side effects. The goal is to make the standard treatment safer, not to cure the disease at this stage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glucarpidase (also called Voraxaze)
What this could lead to: If it works, this could make standard chemotherapy safer by quickly clearing methotrexate from the blood, reducing toxic side effects.
What could go wrong: This is a very early, small pilot study (58 people) focused on safety and drug levels, not on curing the disease. It may not lead to better outcomes or be confirmed in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Cleveland Clinic (Data Collection and Specimen Collection)

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute (Data Collection and Specimen Analysis)

Boston, Massachusetts, 02115, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.